XML 41 R23.htm IDEA: XBRL DOCUMENT
v3.3.0.814

Collaboration and Other Agreements, Takeda Pharmaceutical Company Limited (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | ---
May. 31, 2014 | Sep. 30, 2015 | Sep. 30, 2014 | Sep. 30, 2015 | Sep. 30, 2014 | Dec. 31, 2014
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |
Deferred revenue current |  | $ 7,163 |  | $ 7,163 |  | $ 14,248
Deferred revenue non-current |  | 11,889 |  | $ 11,889 |  | 16,472
Takeda Pharmaceutical Company Limited [Member] |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |
Non-refundable upfront payment | $ 15,000 |  |  |  |  |
Agreement beginning date |  |  |  | May 2014 |  |
Potential license option fee |  | 15,000 |  | $ 15,000 |  |
Upfront fee allocated to agreement | 10,000 |  |  |  |  |
Expected period of development |  |  |  | 24 months |  |
Recognized revenue under agreement |  | 1,300 | $ 1,300 | $ 6,800 | $ 1,700 |
Deferred revenue |  | 3,300 |  | 3,300 |  | 7,100
Deferred revenue current |  | 3,300 |  | 3,300 |  | 5,000
Deferred revenue non-current |  | 0 |  | 0 |  | $ 2,100
Revenue Recognition, Milestone Method, Revenue Recognized |  |  |  | 3,000 |  |
Additional Potential Sales Milestone Payments Under Agreement |  | 375,500 |  | 375,500 |  |
Additional Potential Clinical And Regulatory Milestone Payments Under Agreement |  | 93,000 |  | $ 93,000 |  |
Takeda Pharmaceutical Company Limited [Member] | Research Collaboration And License Option Agreement [Member] |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |
Agreement beginning date |  |  |  | September 2014 |  |
Upfront fee allocated to agreement | $ 5,000 |  |  |  |  |
Research and development services revenue |  | $ 500 |  | $ 1,100 |  |

X
- Definition Additional potential clinical and regulatory payments under agreement. + References No definition available. + Details
Name: | mgnx_AdditionalPotentialClinicalAndRegulatoryMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Aggregate potential sales milestone payments available to be earned under collaboration agreement. + References No definition available. + Details
Name: | mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Date on which the Company entered into agreement. + References No definition available. + Details
Name: | mgnx_CollaborationAndOtherAgreementEnteredDate
Namespace Prefix: | mgnx_
Data Type: | invest:dateStringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Initial fee received from collaboration or license agreement. + References No definition available. + Details
Name: | mgnx_NonRefundableUpfrontFees
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential license option fee. + References No definition available. + Details
Name: | mgnx_PotentialLicenseOptionFee
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Revenue recognized from reimbursement of research and development services. + References No definition available. + Details
Name: | mgnx_ResearchAndDevelopmentServicesRevenue
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Portion of upfront fee allocated to agreement. + References No definition available. + Details
Name: | mgnx_UpfrontFeeAllocatedToAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Refers to upfront payment recognition period. + References No definition available. + Details
Name: | mgnx_UpfrontPaymentRecognitionPeriod
Namespace Prefix: | mgnx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicensesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=51671726&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=mgnx_TakedaPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mgnx_ResearchCollaborationAndLicenseOptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |